Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

112 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Activity and safety of oxaliplatin with weekly 5-fluorouracil bolus and low-dose leucovorin as first-line treatment for advanced colorectal cancer.
Cassinello J, Escudero P, Salud A, Marcos F, Pujol E, Pérez-Carrión R, Colmenarejo A, González del Val R, Valero J, Oruezábal MJ, Guillem V, García I, Arcediano A, Marfà X. Cassinello J, et al. Among authors: pujol e. Clin Colorectal Cancer. 2003 Aug;3(2):108-12. doi: 10.3816/CCC.2003.n.017. Clin Colorectal Cancer. 2003. PMID: 12952567 Clinical Trial.
Multicenter phase II study of fixed sequences of capecitabine combined with oxaliplatin or irinotecan in patients with previously untreated metastatic colorectal cancer.
Cassinello J, Alvarez JV, López MJ, Pujol E, Colmenarejo A, Segovia F, Marcos F, Filipovich E, Arcediano A, Castro IG. Cassinello J, et al. Among authors: pujol e. Clin Colorectal Cancer. 2006 Mar;5(6):429-35. doi: 10.3816/ccc.2006.n.014. Clin Colorectal Cancer. 2006. PMID: 16635282 Clinical Trial.
A multicenter phase II study of irinotecan in patients with advanced colorectal cancer previously treated with 5-fluorouracil.
Méndez M, Salut A, García-Girón C, Navalon M, Diz P, García López MJ, España P, de la Torre A, Martínez del Prado P, Duarte I, Pujol E, Arizcun A, Cruz JJ. Méndez M, et al. Among authors: pujol e. Clin Colorectal Cancer. 2003 Nov;3(3):174-9. doi: 10.3816/ccc.2003.n.023. Clin Colorectal Cancer. 2003. PMID: 14706177 Clinical Trial.
A randomized phase II/III study of cabazitaxel versus vinflunine in metastatic or locally advanced transitional cell carcinoma of the urothelium (SECAVIN).
Bellmunt J, Kerst JM, Vázquez F, Morales-Barrera R, Grande E, Medina A, González Graguera MB, Rubio G, Anido U, Fernández Calvo O, González-Billalabeitia E, Van den Eertwegh AJM, Pujol E, Perez-Gracia JL, González Larriba JL, Collado R, Los M, Maciá S, De Wit R; SOGUG and DUOS. Bellmunt J, et al. Among authors: pujol e. Ann Oncol. 2017 Jul 1;28(7):1517-1522. doi: 10.1093/annonc/mdx186. Ann Oncol. 2017. PMID: 28419193 Free article. Clinical Trial.
Glomus tumour of the palate. Diagnostic and treatment.
Redondo LM, Valerdiz S, Pujol E, Serrat A, Alonso A, Verrier A. Redondo LM, et al. Among authors: pujol e. Med Oral. 1999 Nov-Dec;4(5):626-631. Med Oral. 1999. PMID: 11507532 No abstract available.
Optimized ultrasound neuromodulation for non-invasive control of behavior and physiology.
Murphy KR, Farrell JS, Bendig J, Mitra A, Luff C, Stelzer IA, Yamaguchi H, Angelakos CC, Choi M, Bian W, DiIanni T, Pujol EM, Matosevich N, Airan R, Gaudillière B, Konofagou EE, Butts-Pauly K, Soltesz I, de Lecea L. Murphy KR, et al. Among authors: pujol em. Neuron. 2024 Oct 9;112(19):3252-3266.e5. doi: 10.1016/j.neuron.2024.07.002. Epub 2024 Jul 29. Neuron. 2024. PMID: 39079529
Impact of an antimicrobial stewardship program indicator on the appropriateness of the empiric antibiotic treatment of urinary source Escherichia coli bacteraemia.
Giménez-Pérez M, Hernández S, Padullés A, Boix-Palop L, Grau S, Badia JM, Ferrer R, Calbo E, Limón E, Pujol M, Horcajada JP; Members of the E. coli Study Group, on behalf of VINCat Program. Giménez-Pérez M, et al. Int J Antimicrob Agents. 2024 Aug;64(2):107202. doi: 10.1016/j.ijantimicag.2024.107202. Epub 2024 May 18. Int J Antimicrob Agents. 2024. PMID: 38768736
112 results